C. Carpenter

发表

Prevalence of Norovirus among Visitors from the United States to Mexico and Guatemala Who Experience Traveler's Diarrhea

K. Schwab, A. L. Bourgeois, A. Kärnell, 2005, Journal of Clinical Microbiology.

Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.

A. L. Bourgeois, R. Walker, R. Mckenzie, 2006, Vaccine.

A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC.

M. Finucane, R. Sack, E. Hall, 2008, Vaccine.

Randomized Clinical Trial Assessing the Safety and Immunogenicity of Oral Microencapsulated Enterotoxigenic Escherichia coli Surface Antigen 6 with or without Heat-Labile Enterotoxin with Mutation R192G

E. Hall, D. Tribble, C. Porter, 2008, Clinical and Vaccine Immunology.

Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge.

David N. Taylor, A. Durbin, A. L. Bourgeois, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.

J. O’Neill, David N. Taylor, A. L. Bourgeois, 2006, Vaccine.

Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers.

D. Sack, R. Sack, E. Hall, 2006, Vaccine.

E. Hall, D. Tribble, C. Porter, 2008 .

Systemic Pharmacokinetics of Rifaximin in Volunteers with Shigellosis

David N. Taylor, A. Durbin, A. L. Bourgeois, 2007, Antimicrobial Agents and Chemotherapy.